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Abstract: The clinical course of COVID-19 is variable, with clinical manifestation ranging from 81% mild course to 14% severe course
along with 5% critical course in patients. The asymptomatic course is reported to potentially range between 20% and 70% (avg. 33%). A
more severe course is seen in the elderly, those with various chronic diseases, and the immunosuppressed, where the case fatality rate is
higher in these risk groups. The disease progresses with various symptoms, such as fever, cough, shortness of breath, malaise, myalgia,
taste and smell disorders, diarrhea, sore throat, headache, and conjunctivitis. The disease begins with shortness of breath, indicative of
lung damage, after an average of 7 to 10 days, and progresses in ARDS, sepsis, and septic shock. Some patients quickly enter shortness
of breath, while others gradually develop shortness of breath and chest tightness and burning. The risk factors for a poor prognosis
are age, comorbidities, and changes in laboratory tests. Secondary bacterial and fungal infections frequently develop with steroids and
immunosuppressants, especially in the intensive care unit. Frequent complications in hospitalized patients include pneumonia (75%),
ARDS (15%), acute renal failure (9%), and acute liver injury (19%). An increased incidence of heart damage is observed, including
acute heart failure, arrhythmias, and myocarditis. Of the patients hospitalized due to COVID-19, 10%–25% present with prothrombotic
coagulopathy, resulting in venous and arterial thromboembolic events. The most common extrapulmonary symptom is neuropsychiatric
involvement, frequently accompanied by insomnia, an impediment to remembering, and an altered state of consciousness. During the
course of COVID-19, patients undergo some pathological changes (severe lymphopenia, high levels of C-reactive protein, D-dimer,
ferritin, etc.) depending on the condition and exposure level of the affected systems as shown by various laboratory tests. The relevant
tests are the guiding elements of risk assessment, clinical monitoring, disease severity, and prognosis setting and therapy decisionmaking processes.
Key words: COVID-19, clinical features, risk factors, complications, laboratory tests

1. Introduction
Caused by the agent SARS-CoV-2 and affecting nearly
every country globally, the COVID-19 pandemic has
resulted in laboratory-verified cases nearing 200 million
and over 4,000,000 deaths as of today [1].
SARS-CoV-2 is transmitted through the respiratory
tract by droplets and contact surfaces contaminated by
these droplets (mainly due to hands with the mouth,
nose, and eyes). Additionally, it is transmitted airborne
by droplet nuclei in clinical procedures (clinical sampling
from the respiratory tract) conducted by healthcare
providers [2-5].
Every patient may transmit the infection to 2–3 people
on average. Transmission is likely in the early period (24–
48 h earlier) when there are no symptoms of the disease
[2-5]. Some variants developing worldwide during the
disease process have increased contagiousness [6].

This paper discussed the varied clinical features and
course of COVID-19, providing a further summary of the
status of biochemical and hematological tests identified
during the disease.
2. Clinical features
The incubation duration of COVID-19 ranges from 2
to 14 days; in many cases, clinical symptoms develop
approximately 4 to 5 days after exposure (average
incubation time is 4–5.1 days) [7-10]. A study revealed
that the symptom onset occurred on average 4 days (3–7
days) after the first positive RT-PCR test [11].
The rate of patients with recent-onset symptoms
(shown within 2.2 days) is 2.5%, and 97.5% of those
infected were reported to have developed symptoms
within 11.5 days [5,7-10].
Some publications support that those exposed to
the disease without clinical symptoms are higher than
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expected (20%–70%), and these people are critical
regarding transmission [2,5,10].
The virus starts to be contagious 24 to 48 h before
the symptom onset and remains contagious for 7 to
12 (8) days in mild/moderate cases after the onset of
symptoms, where it takes longer than 2 weeks in severe
cases; however, positive PCR test results may continue
for 6 to 8 weeks [2,5,10].
2.1. Severity of the disease and case fatality
COVID-19 is undergoing a critical or severe course
ranging from asymptomatic infection to mild or severe
respiratory failure; most infections are not severe [2,5,1216].
The severity index is summarized in Table 1 [5,11,16]
when the reported severity information is reviewed.
The infection is mild or asymptomatic in 80%–
90% of the cases. Only 10% of cases are severe due
to dyspnea, hypoxemia, and significant radiological
impairment (>50%) of pulmonary parenchyma. About
5% of cases become critical illness and respiratory
failure, pneumonia, shock, and multiorgan failure. The
most severe cases are accompanied by death due to
usual progression to ARDS and multiple organ failure.
Generally, this is common in high-risk individuals,
such as the elderly and those affected by multiple
morbidities. Typically, the affected individuals show
varying degrees of dyspnea and radiological symptoms
[5,15-23]. In addition, respiratory failure was reported
to have developed without a subjective sensation of
dyspnea (“silent hypoxemia”) [21]. In these cases,
hypocapnia caused by compensatory hyperventilation is
an accompanying finding [5].

The spectrum of disease severity and the case fatality
rate may vary between countries and even between regions
in countries. The estimated fatality rate among infected
individuals is relatively low since many COVID-19
infections are asymptomatic, and milder infections are
not diagnosed. Based on some analyses, lower and higher
rates are also estimated to be between 0.15% and 1%,
with significant heterogeneity by reporting location and
risk groups [24,25]. The case fatality rate is between 5.8%
in Wuhan of China and 0.7% in China [5,17]. There is a
higher rate of critical and life-threatening illness among inpatients [19-21]. A study conducted in the US reported the
fatality rate among hospitalized patients at 24%, with the
fatality rate reported to be 60% in patients using mechanical
ventilation in intensive care units [21].
In Italy, 12% of all the patients diagnosed with
COVID-19 and 16% of hospitalized patients were admitted
to intensive care units. The estimated case fatality rate was
7.2% in mid-March 2020 [5,26,27]. On the other hand,
South Korea had an estimated mortality rate of 0.9%
by mid-March. This might be correlated with different
demographic features of the infection; the median age of
the infected patients is 64 years in Italy, while the median
age in Korea is around 40 years [2,5,15].
The variance between several studies is likely to result
from distinct patient features (especially elderliness and
comorbidities) and/or infection prevalence rates affected
by the relative number of diagnostic tests performed on
symptomatic individuals [2,17,28-34].
2.2. Risk factors for severe illness
Symptoms or more severe clinical courses are likely in
healthy individuals of any age. However, they have mainly

Table 1. Severity of SARS CoV-2 infection, with typical features.

Estimated
prevalence

Severity

Indicators

Asymptomatic

Absence of typical or atypical clinical manifestations; no changes in X-ray and/or
CT scans

Mild disease

Fever, cough, sore throat, nausea/vomiting, diarrhea, loss of taste or smell but no
dyspnea; normal O2 saturation and usually no changes in X-ray and/or CT scans

Moderate disease

Symptoms of mild disease plus evidence of lower respiratory tract infection (exam
and/or imaging (presence of ground-glass opacities and lung consolidation), O2
saturation ≥94% on room air

Severe disease

Symptoms of moderate disease but O2 saturation <94%, PaO2/FiO2 <300 mmHg,
respiratory frequency >30 breaths per minute, or chest imaging showed obvious
lesion progression more than 50% within 24–48 h

15%

Critical disease

Symptoms of severe disease but intubated with respiratory failure, septic shock,
and/or multiorgan dysfunction; ground-glass opacities (usually bilateral), lung
consolidation, pulmonary nodules.

5%

80%
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been seen in the elderly or adults with underlying medical
comorbidities (cardiovascular diseases, diabetes, chronic
lung diseases, etc.) [2,35]. The risk factors for severe
diseases are shown in Table 2. Comorbid diseases increase
mortality. The rate of preexisting comorbidities was 2.7 in a
subgroup of 355 patients deceased from COVID-19 in Italy,
where only three patients had no underlying problems [27].
Deaths are increasing in older adults. The death rate in
elderly patients was considerably higher [5,17,27-36]. A
report from the Chinese Center for Disease Control and
Prevention found that the case fatality rate was 12% and
15% in a group of people aged 70 to 79 years and people
aged 80 years and over, respectively, contrary to the fatality
rate of 2.3% in all cohort studies [17]. Similar findings
have also been reported in Italy, where mortality rates
were 12% for people aged 70–79 and 20% for people aged
80 and over [26]. Sixty-seven percent of the cases in 2449
patients diagnosed with COVID-19 in the US included the
population aged ≥45, and similar to the findings in China,
the elderly had the highest fatality rate, and the population
aged ≥65 years constituted 45% of all the hospitalized
patients, 53% of ICU patients, and 80% of deaths. There
were no critical care patients or deaths among the
population 19 years of age or younger [29].
The rate of severe or life-threatening infections and the
need for intensive care were also determined at varying
rates in different countries/regions and clinical series [2,5].
In males, a disproportionately high number of deaths have
been reported from China, Italy, and the United States [5].
COVID-19 was observed to result in a disproportionately
high rate of infection and death, possibly connected with
the underlying inequalities in social determinants of health
among the black population and Latinos in the United
States of America [5].
Symptomatic infection is rare in children; cases are
usually mild when they occur, whereas severe cases are
reported [5].

Specific laboratory features, such as lymphopenia,
elevated inflammatory markers (C-reactive protein [CRP],
IL-6, ferritin, etc.), increased liver enzymes, increased
lactate dehydrogenase (LDH), high D-dimer (>1 µg/mL),
prolonged prothrombin time, high troponin, increased
creatine phosphokinase (CPK), and kidney dysfunction,
were associated with worse results [5,31-36] (Table 2).
Viral factors (high viral load, viremia) and other genetic
factors are associated with the severity of the disease [5].
2.3. Asymptomatic infections
New case series show that asymptomatic infections,
which were reported to be low at the initial diagnosis of
the disease, are common (20%–70%) [5,6,16,32,33]. A
publication evaluating 14 individual studies found that
33% of people infected with SARS-CoV-2 never developed
symptoms [41].
Nearly half of the passengers with positive COVID-19
test results as scanned in the cruise ship “Diamond
Princess” were asymptomatic during diagnosis; some
of these passengers developed symptoms later [5,18].
Asymptomatic cases were found to be higher in especially
in the younger population [42,43].
Even patients with asymptomatic infections likely have
objective clinical abnormalities (low-grade fever, glass
opacity in the scanner, irregular shading, etc.). In some
asymptomatic cases, different clinical symptoms may
subsequently appear [5,18,36,41].
2.4. Clinical symptoms
COVID-19 often begins with a fever (which develops after
other complaints in some cases), followed by tiredness, dry
cough, and muscular pain [5,14,29,36].
Other cohort studies of the patients with confirmed
COVID-19 infection reported similar clinical symptoms
[2,5,12,13,36]. Additionally, fever reported at very high
rates in initial studies was reported at lower rates in
subsequent series; the fever reported in some series was

Table 2. Proven or potential epidemiological risk factors for severe COVID-19* [5,21,28,37-40].
a) Age > 65
b) Cardiovascular disorder
c) Diabetes mellitus
d) Chronic obstructive pulmonary disease and other pulmonary diseases
e) Cancer (especially hematological malignancies, lung cancer, and metastatic disease)
f) Chronic kidney disease
g) Solid-organ or hematopoietic stem cell transplant
h) Obesity (BMI ≥ 30)
i) Smoking
BMI: Body mass index
* Among the associated risk factors, those identified clinically are presented in Table 4 below.
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lower than 38 degrees (approximately 20% of the cases)
[5,13]. Notably, fever was detected during hospitalization
in the first publications, where the fever was detected at a
high level (late period) (5, 10, 13). In a study conducted in
New York, 31% of patients (>5000 patients) hospitalized
for COVID-19 had a fever exceeding 38 degrees [19].
The most common severe manifestation of COVID-19
is pneumonia, characterized primarily by fever, cough,
shortness of breath, and bilateral infiltrates on chest
imaging [5,10,12-14]. In addition, other common features
include upper respiratory tract symptoms, myalgia,
diarrhea, and olfactory or gustatory disorders. While
dyspnea that develops several days after symptom onset
provides insight, no specific clinical feature reliably
distinguishes COVID-19 from other viral respiratory tract
infections [2,5,36].
COVID-19 may cause shortness of breath one week
after symptoms appear, requiring in-patient treatment
in nearly 20% of patients. These symptoms progress
into pneumonia in some patients, accompanied by chest
tightness, chest pain, and shortness of breath, especially
in the elderly and those with chronic health conditions
[5,36].
Many studies identifying clinical features of COVID-19
were conducted among the hospitalized populations. As
many studies have revealed, clinical symptoms and their
frequency are presented in Table 3 [2,5-12,36].
2.5. Clinical course
The symptomatic infection may vary from mild to critical
during the disease. In most patients (80.9%), infections are
mild (with symptoms like the flu) and may be treated at
home, 13.8% are severe, leading to severe diseases, such as
pneumonia and dyspnea; 4.7% are very severe, resulting
in respiratory failure, septic shock, and multiple organ
failure. These rates are partly variable in different patient
groups [2,5,10-14,36].
The disease can progress during a week in some
patients without severe initial symptoms. Some mild cases
may rapidly become critical. Conditions in moderate cases
may worsen more frequently; therefore, this group of
patients should be monitored more carefully [5,36].
Patients usually arrive at the hospital on the 4th day
from the first symptoms, while mild respiratory distress
develops on the 5th day. From the onset of symptoms,
hospitalization takes an average of 7 days (4.0–8.0), and
respiratory distress occurs on day 8 on average (5.0–13.0),
and ARDS on day 9 on average (8.0–14.0). Mechanical
ventilation requires an average of about 10.5 days (7.0–
14.0) [2,5,12,13,36].
The typical course of severe pathology includes overt
dyspnea 6 days after the onset of flu-like symptoms,
hospitalization after 8 days, and the need for tracheal
intubation 10 days after hospitalization [2,5].

Table 3. Clinical symptoms identified in several studies [2,5,1014,36].
Symptoms

Frequency (%)

Fever

43–98

Dyspnea

19–64

Cough

50–82

Fatigue

40–70

Loss of appetite

40–50

Expectoration

14–44

Runny nose

4–24

Sore throat

5–14

Taste and smell dysfunctions

24–60*

Headache

5–34

Diarrhea

2–19

Nausea-vomiting

3–16

Muscle pain

11–36

*Lower in some series (<10%)

Many of the patients have a good prognosis.
The recovery period for mild infection seems to be
approximately 2 weeks and 3 to 6 weeks for severe cases.
The length of time between clinical onset and death ranges
from 2 to 8 weeks [2,5,35].
Currently, the number of patients required to be
hospitalized is unknown. Approximately 10%–20% of
hospitalized patients require intensive care, whereas
intubation is required for 3%–10%. The mortality rate for
these patients is 2.5% [2,5,10,36].
The disease becomes more severe among the elderly
and those suffering from other related conditions (heart
disease, hypertension, kidney failure, diabetes, etc.). While
the case fatality rate in the population aged under 50 years
(with no additional conditions) is low, the risk of fatality is
much higher (>10%) in the population aged over 60 years,
especially among those aged 70–80 years [2,5,36].
Pediatric patients generally present with mild
symptoms. The progression of the illness in pregnant
women is similar to that observed in people of the same age
group. There is no evidence of intrauterine transmission so
far [2,5,36,44].
2.6. Severe and critical illness
While most patients with COVID-19 are asymptomatic
or have mild SARS-CoV-2 infections, many patients have
been admitted to the hospital and ICU. Mortality rates are
high during the 2019 Coronavirus Disease (COVID-19)
outbreak; the increase in the number of patients requiring
an ICU has been overwhelming, jeopardizing most critical
care capabilities in hospitals worldwide [45].
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Severe and critical cases comprised 14% and 5% of
laboratory-confirmed COVID-19 patients, respectively.
Clinically, most patients infected with “Severe Acute
Respiratory Syndrome Coronavirus 2” (SARS-CoV-2)
exhibit no significant symptoms. However, almost 5% of
the patients show a severe lung injury or even a “Multiple
Organ Dysfunction Syndrome (MODS),” with mortality in
intensive care units between 8% and 38%, depending on
the country [46].
In a CDC report of 4226 individuals with COVID-19 in
the United States between March and February 2020, the
overall death rate for patients with COVID-19 was 2.3%,
but that was for those requiring treatment and mechanical
ventilation due to >50% hypoxemic respiratory failure
[30].
Our clinical observations indicate that diabetes
mellitus (primarily type 2) and underlying heart disease
lead to a more severe and life-threatening progression of
COVID-19, as well as morbid obesity and autoimmune
diseases (Table 4).
2.6.1. Severe pneumonia
Severe pneumonia should be considered in patients with
tachypnea, chest retraction, or inability to eat or drink. In
10% to 20% of severe patients, the airway injury inevitably
develops into acute respiratory distress syndrome
(ARDS), defined as the oxygen partial pressure (PaO2)
up to the proportion of inhaled oxygen (FiO2) during
8–14 days of illness, the ratio of less than 300 mmHg, as
well as resulting noncardiogenic pulmonary edema and
mechanical ventilation. ARDS, as the leading cause of
respiratory failure, is associated with high morbidity and
mortality. Risk factors for developing severe to critical
cases are advanced age, underlying comorbidities such as
high blood pressure, diabetes, cardiovascular diseases, and
cerebrovascular diseases [47].

Severe cases are confirmed if one of the following
points is met: (a) shortness of breath, breathing rate ≥ 30
breaths/min; (b) pulse oxygen saturation (SpO2) ≤ 93% of
the room air at rest; (c) arterial oxygen partial pressure
(PaO2)/proportion of inhaled oxygen (FiO2) ≤ 300 mmHg.
At higher altitudes (over 1 km), the PaO2/FiO2 values
should be adjusted based on the equation PaO2 / FiO2 ×
[atmospheric pressure (mmHg) / 760]; (d) patients with
>50% lesion progression within 24 to 48 h on lung imaging
[48]. The chest CT and the evolution of the CRP of a severe
case of pneumonia are illustrated in Figures 1 a–1c.
The mean time from symptom onset to pneumonia
development is about 5 days. In the meantime, from
symptom onset to the commencement of severe hypoxemia
and being hospitalized in the ICU is about 7–12 days [29].
Most patients have bilateral opacities on chest
X-ray and tomography. The most common findings on
tomography are ground-glass opacities and consolidation.
In patients admitted to the ICU, acute respiratory distress
syndrome (ARDS) with acute hypoxemic respiratory
failure—sometimes with severe hypercapnia—is the most
common complication (60%–70%), followed by shock
(30%), myocardial dysfunction (20%–30%) and acute
kidney injury (10%–30%). Elderly patients may develop
hypoxemia without respiratory distress. Arrhythmia is
observed in nearly half of the patients [49]. Some notable
laboratory parameters for mild/moderate and severe/
critical patients that were followed in our hospital are
shown in Table 5.
2.7. Critical COVID-19
In critical cases, patients complained of respiratory failure
(severe dyspnea, shortness of breath > 30/min, tachypnea,
hypoxia), fever, reduced blood oxygen saturation of less
than or equal to 93%, and pulmonary filtrates, shock, and
multiorgan dysfunction, or even failure. Research has

Table 4. Risk factors for severe/critical diseases (unpublished data from Kayseri City Training and Research
Hospital).
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Demographics

Mild/moderate
n = 39 (%)

Severe/critical
n = 19 (%)

p

Age (mean ± SD, years)
Male sex
COVID-19 compatible chest CT signals
Chronic obstructive pulmonary disease
Hypertension
Diabetes mellitus
Coronary artery diseases
Chronic renal failure
Body mass index

46.5 ± 15
21 (54)
15 (38)
24 (36)
11 (28)
16 (19)
15 (18)
5 (6)
25 ±3.1

67.4 ±12
10 (53)
15 (79)
6 (32)
10 (52)
9 (50)
5 (26)
4 (21)
27.1±4.8

<0.01
0.9
0.05
0.2
0,07
<0.01
0.4
0.03
0.057
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1.2

27.05.2021

31.05.2021

Figure 1. A sample for “severe disease” related to COVID-19. Thoracic CT imaging and CRP course of a 53-year-old male COVID-19
patient with hypertension and coronary artery disease as comorbidities. A) CT imaging at admission had a fever and CRP: 26 mg/dL,
commenced dexamethasone at 2 × 8 mg/day. B) Progression of CT imaging on the 9th day of hospitalization. A single dose of 80 mg
tocilizumab and dexamethasone 2 × 8mg/day for 10 days were ordered. C) CRP course of the patient.

also shown that, under severe conditions, patients show
signs of impaired breathing, wet rattles, dull percussion,
and a decrease in tactile tremor. Apart from respiratory
problems, the disease also causes gastrointestinal issues
like diarrhea. Laboratory tests of a complete blood count
may show an average or reduced white blood count or a
reduced lymphocyte count at the beginning of the onset of
the disease. Patients also have higher levels of C-reactive
protein. The chest CT series and the progression of the
CRP of a critical case are illustrated in Figures 2a–2d.
Critical cases are recognized when one of the following
points is met: (a) respiratory failure occurs, and mechanical
ventilation is required; (b) shock occurs; (c) complicated

with other organ failures that require monitoring and
treatment in the intensive care unit (ICU); individuals who
have acute respiratory failure, septic shock, and/or multiple
organ dysfunction. Patients with severe COVID-19
illness may become seriously ill due to the onset of “acute
respiratory distress syndrome” (ARDS), which tends to
occur approximately one week after symptoms appear [50].
2. 8. Acute respiratory distress syndrome (ARDS)
In patients with respiratory manifestations of SARS-CoV-2
infection, hypoxemic respiratory failure may occur. After
the onset of shortness of breath, patients initially appear to
have good lung compliance and poor lung elasticity, and an
inadequate response to positive expiratory pressure (PEP);
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Table 5. Laboratory features of the patients at admission time associated with severe/critical COVID-19
(unpublished data from the Kayseri City Hospital).
Patients
Variables (unit, normal values)

Mild/moderate
(n = 39)

Severe/critical
(n = 19)

p

White blood cell count, ×10³μL
(4.5–10)

5.7 (4.8–7.3)

8.8 (6.5–10.3)

0.002

Neutrophils, x10³μL
(1.8–7.5)

3.5 (2.6–5.1)

6.3 (3.9–9.1)

0.001

Lymphocytes, x10³μL
(1.1–3.2)

1.6(1.3–1.9)

1.1 (0.8–1.7)

0.021

Lactate dehydrogenase, U/L
(135–214)

210 (189–271.0)

325.5 (233.0–376.0)

0.004

Ferritin, µg/L
(30–400)

123.0 (79.0–228.0)

473.0 (206.0–902.0)

0.001

C–Reactive Protein, mg/dL
(0–5)

6.9 (1.7–30.6)

93.0 (47.0–137.0)

<0.001

D–dimer, µg/L
(0–500)

390.0 (290.0–670.0)

1010.0 (685.0–580.0)

0.002

some patients may then progress to an acute respiratory
distress syndrome, which is characterized by high elasticity
and low compliance, as well as a high PEP response. In
addition, it appears that endothelial damage is occurring,
resulting in disruption of pulmonary vasoregulation and
inadequate ventilation and perfusion. ICU admission and
mechanical ventilation rates vary from report to report,
possibly due to differences in age, admission threshold,
mechanical ventilation, and the timing of the study
conducted with the time of the pandemic [51].
Oxygenation disorder in adults:
· Mild ARDS: 200 mmHg <PaO2/FiO2a ≤ 300 mmHg
(PEEP or CPAP ≥ 5 cmH2O).
· Moderate ARDS: 100 mmHg <PaO2 / FiO2 ≤ 200
mmHg (≥ 5 cmH2O with PEEP).
· Severe ARDS: PaO2 / FiO2 ≤ 100 mmHg (with PEEP
≥ 5 cmH2O) (52).
2. 9. Sepsis and septic shock
Patients with COVID-19 and sepsis are thought to
be the most critical. The accompanying multiorgan
dysfunction results from a deregulated host response
to infection. Signs of organ dysfunction include severe
dyspnea, low oxygen saturation, decreased urinary
output, tachycardia, hypotension, cold extremities, skin
patches, and impaired mental status. Laboratory evidence
of other homeostatic disorders includes acidosis, lactate
elevation, hyperbilirubinemia, thrombocytopenia, and
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signs of coagulopathy. Blood pressure of patients with
septic shock is continuously decreased despite the volume
of resuscitation. They may also have an associated serum
lactate level of> 2 mmol / L [53]. The chest CT series and
the CRP progress of a MODS and ARDS are shown in
Figures 3a–3d and Figures 4a–4d, respectively.
2. 10. Complications
Complications of COVID-19 included pneumonia, acute
respiratory distress syndrome, heart damage, arrhythmia,
septic shock, liver dysfunction, acute kidney injury
(AKI), and multiple organ failure. Approximately 5%
of COVID-19 patients and 20% of hospitalized patients
present severe symptoms requiring critical care. The
most common complications in hospitalized patients are
pneumonia (75%), ARDS (15%), acute kidney injury [AKI
(9%)], and acute liver injury (19%). A growing quantity
of heart damage has been found, including increased
troponin levels, acute heart failure, arrhythmias, and
myocarditis. Of hospitalized COVID-19 patients, 10%–
25% develop prothrombotic coagulopathy, which results in
venous and arterial thromboembolic events. Neurological
manifestations include altered consciousness and stroke
[48]. A variety of disease-related complications and their
physio-pathological mechanisms were summarized in
Table 6. The thoracic CT series and CRP progression
of a case complicated by pneumothorax and invasive
pulmonary aspergillosis are shown in Figures 5a–5e.
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15.6
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4.2
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9.4
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6.9

7

7.7

Patient follow-up days

Figure 2. A sample for critical disease associated with COVID-19. Thoracic CT imaging and CRP course for 51-year-old women
COVID19 patient with previously undiagnosed type II diabetes mellitus. A) Thoracic computed tomography at admission. B) Thoracic
CT imaging on day eight. C) Thoracic CT imaging on the 37th day. D) Patient’s CRP course. Low-dose tocilizumab (100 mg, 100 mg,
every other day at first CRP peak, and 80 mg, and 80 mg one dose at second CRP peak, every other day) four times (a total of 360 mg)
and 250 mg three times for 3 consecutive days methylprednisolone and 40 mg/day for 20 days had been administered.

2. 11. Viral and bacterial coinfection and secondary
infection in patients with COVID-19
According to current estimates, there is generally a low
rate of new, real viral coinfections at the beginning of
COVID-19. Reports of high coinfection rates are expected
to be tempered by the limitations of current diagnostic
methods. Nevertheless, more data collection is warranted,
and more information about COVID-19 coinfections
will provide better guidance for effective antimicrobial
treatment, whether SARS-CoV-2 coinfections or genuine
coinfections [55].
In a multicenter study by Russell et al. [56], 1107
patients/48,902 patients (2.26%) were identified as having
COVID-19-related infections (positive blood, sputum, or

deep breathing cultures). For microbiologically confirmed
COVID-19-associated infections where sampling time was
known, 762 (70.6%) of the 1080 infections were secondary
and occurred more than 2 days after hospitalization.
Most culture-positive respiratory samples represented
secondary infections (919 [4.9%] of 1082 sputum and
deep respiratory cultures). In lower respiratory tract
coinfections (within 2 days of admission), Staphylococcus
aureus (17.8%), Haemophilus influenzae (12.7%),
and Pseudomonas aeruginosa (9.3%) were most frequently
identified in sputum. Streptococcus pneumoniae was
infrequently cultured (4·2%). Staphylococcus aureus was
the predominant organism (31.1%). S. aureus was the
common cause of secondary lower respiratory tract
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Figure 3. A sample for sepsis/septic shock and MODS associated with COVID-19. A 54-year-old male with type 2 diabetes complained
of shortness of breath (SaO2: 77) and weakness and was monitored in the ICU. A) Chest CT at the time of admission (CT) showed a
typical ground glass image that corresponded to a COVID-19 peripheral weighted bilateral multifocal patchy. B) Chest CT on day nine
at hospitalization. C) Chest CT on day 23 and out of the hospital with an oxygen condenser. D) CRP course of the patient.

infections (sputum: 12.6%; deep respiratory: 10.5%), but
most organisms were gram-negative, including Escherichia
coli (14.5%), Pseudomonas aeruginosa (12.5%), Klebsiella
pneumoniae (11.8%), Klebsiella aerogenes (6.2%), and
Citrobacter koseri (4.0%) [57].
2. 12. Extrapulmonary involvement of COVID-19
2. 12. 1. Neurologic involvement
In patients with severe or critical comorbidities,
neurological complications occur frequently. Central and
peripheral nervous systems (CNS and PNS) may be affected
during COVID-19. CNS symptoms include headache,
and decreased reactivity are initial indicators of potential
neurological impairment; anosmia, hyposmia, hypogeum,
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and dysgeusia are also common early symptoms of
coronavirus disease. Headache is a commonly occurring
symptom. The most severe neurological manifestation,
sensory impairment (agitation, delirium, and coma), is
caused by hypoxia and metabolic abnormalities [58].
Cerebrovascular disease, particularly large-vessel
ischemic strokes, and less frequently cerebral venous
thrombosis, intracerebral hemorrhage, and subarachnoid
hemorrhage, usually occur as part of a thrombotic state
induced by viral attachment ACE2 receptors in the
endothelium. In addition, acute hemorrhagic necrotizing
encephalopathy is associated with cytokine storms [59].
Additionally, individual cases of convulsions,
encephalopathy, meningitis, encephalitis, and myelitis
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Figure 4. The same patient (a 54-year-old male) was hospitalized again after a 12-day discharge with severe signs of ARD. A) On the day
of admission, he vented mechanically. B) 3rd day of re-admission, and C) 6th day of re-admission, D) The patient’s CRP course lost 43rd
day because of septic shock and multiple organ failure.

have been reported. However, in the case of COVID-19,
neurological diseases affecting PNS and muscles are less
common. They include Guillain–Barré syndrome, Miller
Fisher syndrome, cranial polyneuritis, and rare cases of
viral myopathy accompanied by rhabdomyolysis [60].
2. 12. 2. Psychiatric involvement
There has been an increase in anxiety, mood, sleep,
substance use, and posttraumatic stress disorders after
epidemics. In addition, anxiety related to illness, social
and economic issues, and quarantine may cause more
stress and depressive symptoms in individuals during
the pandemics. In particular, people who contract the
disease, those at heightened risk for it (including the
elderly, people with compromised immune function, and

those living or receiving care in congregate settings), and
people with preexisting medical, psychiatric, or substance
use problems are at increased risk for adverse psychosocial
outcomes [61].
2. 12. 3. Cutaneous involvement
In an international study, the most common dermatological
morphologies were found in 171 laboratory-confirmed
cases of COVID-19, including morbilliform (22%),
perniform (18%), urticaria (16%), macular erythema
(13%), vesicular (11%), papulosquamous (9.9%), and
retiform purpura (6.4%) [62].
2. 12. 4. Cardiac involvement
Coupled with the high inflammatory load associated
with cytokine release, COVID-19 can trigger vascular
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Table 6. Complications of severe COVID-19 infection [54].
Complication

Inflammatory response

Structural abnormalities

Clinical outcome

Abnormal coagulation and
thrombosis

Lymphopenia
Thrombocytopenia
IL-6, CRP
D-dimmer

Venous thrombosis
Intravascular coagulopathy,
Myocardial injury
Cerebral infarction

Deep vein thrombosis
DIC
Myocardial infarction
Stroke

Acute cardiovascular
syndrome (ACovSC)

 roponin
T
¯ST or ST
Arrhythmias

Wall motion abnormalities,
De novo systolic dysfunction
Myocarditis or myocardiopathy

Heart failure
Pericardial effusion
Acute coronary artery disease.

Acute respiratory distress
syndrome (ARDS)

Alveolar damage Influx of
inflammatory cells
Protein exudation

Pulmonary edema
Pneumonia, Pleural effusion
Secondary bacterial infection

Acute dyspnea
Severe hypoxia
Respiratory failure

Cytokine storm syndrome
(CSS)

Macrophage activation
Cytokine release
Thrombin ¯Anticoagulants

Activation of coagulation pathways DIC
Widespread microthrombi,
Shock
Vascular permeability
Multiorgan failure

inflammation, acute myocardial injury, myocarditis,
arrhythmias, venous thromboembolism, metabolic
syndrome, and Kawasaki disease. The most frequently
reported cardiovascular complications of COVID-19
include acute myocardial injury, myocarditis, myocardial
infarction, heart failure, cardiomyopathy, arrhythmias,
and venous thromboembolic events [63].
A case series evaluated cardiovascular events included
84 patients from Morocco; 50 had a pulmonary embolism
(59.52%); three of them were massive. Twelve patients
had a myocardial infarction (14.28%), ten had pericarditis
(11.9%), and three developed myocarditis (3.57%). In
addition, six patients had ischemia (7.14%), including two
patients with Leriche syndrome (in one case associated
with segmental pulmonary embolism), three patients
with lower limb ischemia, and only 1 case of upper limb
ischemia. There were also 2 cases of ischemic stroke
(2.38%) and 1 case of congestive heart failure (1.19%) [64].
2. 12. 5. Renal involvement
A recently published study assessed over 1000 cases of
COVID-19 in China and found that the prevalence of
acute kidney injury (ARI) in these patients was 1.6% (2).
Another study conducted at a university hospital in Wuhan
City in China evaluated 701 COVID-19 patients and found
that the overall prevalence of ARI caused by COVID-19
was 3.2% (3). Another interesting neurological conclusion
was that 43.9% of patients had proteinuria when admitted,
and 26.7% had hematuria. Rhabdomyolysis is commonly
observed in COVID-19. It can lead to high levels of serum
phosphokinase creatinine (more than five times the upper
bound of the ordinary) and could be another critical factor
in ARI development [65].
2. 12. 6. Endocrine involvement
To date, evidence indicates that COVID-19 can induce a
functional pituitary gland by direct and indirect effects
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on the hypothalamus-pituitary axis, resulting in an
inappropriate response to adrenal stress. Furthermore,
there are several reports of potential immune damage
to the thyroid gland leading to subacute thyroiditis.
COVID-19 has been implicated in high blood glucose in
known diabetics and the discovery of insulin resistance
in previously undiagnosed people. It has also been shown
that COVID-19 triggers type 1 diabetes associated with
ketosis. The presence of the virus in semen currently has
no apparent clinical significance [66].
2. 12. 7. Gastrointestinal features
The prevalence of gastrointestinal symptoms at the time of
diagnosis differs from study to study, ranging from 2% to
57%. For example, in a metaanalysis of 35 studies in China,
mainly conducted in the first phase of the epidemic, the
clinical characteristics of 6686 COVID-19 patients were
analyzed, finding a combined prevalence of gastrointestinal
symptoms by 15%. In addition, transient elevations in
serum aminotransferases and altered markers of liver
function and bilirubin have been observed in up to 58% of
patients with severe COVID-19. However, the underlying
mechanisms and possible complications are still poorly
understood [67].
2.12.8. Ocular involvement
In studies that reported details of observed eye symptoms,
the most common eye symptoms were dry eye or foreign
body sensation (16%), redness (13.3%), tearing (12.8%),
itching (12.6%), eye pain (9.6%), and discharge (8.8%) [68].
3. Laboratory tests
During the course of COVID-19, patients have various
pathological changes as indicated by laboratory tests. The
publications on these changes in laboratory tests increased
over time, and the results of different studies were initially
assessed and analyzed [2,5,34-36].

ÇELİK and ÖZTÜRK / Turk J Med Sci

300
280
260

285.4
276.4

D
258.8

248

240
220
200
171.6

180
160
140

153.8

123.2

120
100

87.4

80

65.7

60

52.1

42.9

40

25.5

24.7

20

12.1

7.9

0

380
360
340
320
300
280
260
240
220
200
180
160
140
120
100
80
60
40
20
0

354.3

5.8

4.3

3.2

3.1

13.4

3

E
293.8

249.2

273.4
233.7

218.1
199.9

191.5

167
111.1
87.6

61.4

76.7
69.3

234.7

218

241.7

224.7
205.5

253.7

240.6
194

188.1

126.9
67.8

45.1

37.2

69.7

38.6

Figure 5. A 73-year-old male patient was admitted to our hospital for a critical illness related to COVID-19. A) The chest computed
tomography results were compatible with CORADS-5. B) Pneumothorax (red line) and invasive fungal infection are seen as a mass with
a peripheral halo (orange line) of ground-glass opacification on day 20th of hospitalization in the ICU. C) Reversed halo sign (RHS)
in the left upper lobe (green line) with adjacent ground-glass opacities at the 43rd day of hospitalization in ICU. D & E) Patient’s CRP
course. Aspergillus niger was recovered from bronchoalveolar lavage fluid sample, and galactomannan in bronchoalveolar lavage fluid
antigen test was reported as “positive: 7.19” (0.16–0.2 index).
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The disorders diagnosed upon hematological,
immunological, and biochemical tests are usually
diagnosed in hospitalized patients. The summary
information on the tests used in this context is given in
Table 7.
Laboratory tests guide severity and risk assessment,
clinical monitoring, and therapy decision-making
processes [34,35].

As laboratory findings in hospitalized patients, some
values (CRP, sedimentation rate, LDH, ferritin, etc.)
increase at varying levels along with low lymphocyte count
and high liver enzymes [2,5,36].
The most common laboratory findings in COVID-19
patients are elevated CRP levels, decreased albumin levels,
increased ESR, lymphopenia, eosinopenia, increased IL-6,
and increased LDH.

Table 7. Common laboratory findings among hospitalized patients with COVID-19* [2,5,34-36].
Tests

Changes and interpretations

Hematological parameters (including hemostasis and coagulation)

Complete blood count
(hemogram)

Hemoglobin (usually normal, may be decreased in severe cases)
Leukocyte (normal, decreased, increased (in ICU cases))
Lymphopenia (in most cases), <800 μL in severe cases
Eosinopenia (in most cases)
Thrombocyte (normal, increased, slightly lower in severe cases; thrombocytopenia is linked to the
disease severity and the mortality risk.

CD4 and CD8

Decreased (in most cases)

PT and aPTT

Normal, slightly prolonged (in severe cases, especially in ICU cases); identification of coagulopathy

Fibrinogen

Decreased; identification of continued coagulopathy

D-dimer

Increased (in severe cases; in nonsurvivors); >1000 ng/mL: in severe cases; identification of continued
consumption and thrombotic coagulopathy

Inflammatory Markers
CRP

Increased (Higher in severe cases); > 10 × the upper limit of normal (N: <8 mg/L)

Erythrocyte sedimentation
rate

Normal, increased

Ferritin

Increased (in severe cases); >500 µg/L (N: 10/30–200/300 µg/L)

Procalcitonin

Normal, Increased (In severe cases, secondary to bacterial pneumonia in ICU patients)

Il-6

Increased (according to severity: >critical>severe>mild; cytokine storm)

Biochemistry tests
Glucose

Increased (in severe cases); a marker of metabolic balance

BUN and creatinine

Increased (in severe cases); a marker of renal damage and failure

Electrolytes

Hyponatremia, hypokalemia (hyperkalemia in some patients), Hypocalcemia; a marker of metabolic
balance

Albumin

Decreased (in severe cases; a marker of liver failure; associated with increased mortality)

ALT and AST

Increased (especially in ICU cases; usually as a result of cytokine storm or drug-induced liver injury)

Total Bilirubin

Increased (in severe cases and/or prolonged cases of hospitalization); as a result of liver injury

Lactate dehydrogenase

Increased (in severe cases, in ICU cases, in ARDS cases); >245 U /L in severe cases (N: 110–210 u/L); a
marker of lung injury and tissue damage

Creatine phosphokinase

Increased in severe cases; > 2 × the upper limit of normal (N: 40–150 U/L)

Troponin T/I

Increased (in severe cases), > 2 x the upper limit of normal (N: 0–9/14 ng/L)

B-type natriuretic peptide
(BNP/NT-proBNP):

Increased (in severe/critical cases)

*Of these general laboratory features, the ones identified by us clinically are discussed in relevant sections above.
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As revealed by several studies, the most common
laboratory abnormalities reported at admission among
hospitalized pneumonia patients include leukopenia
(9%–34%) or leukocytosis (24%–30%), lymphopenia
(63%–83%), thrombocytopenia (34%), and elevated
aminotransferase (37%) and lactate dehydrogenase
[2,5,10,12-14,34-36].
Increased
inflammation
indices,
including
nonincreased procalcitonin and increased CRP levels,
are associated with clinical severity. At admission,
many patients with pneumonia have normal serum
procalcitonin levels; however, this level could likely be
higher in patients who need care in ICUs [5,9,29-31]. High
CRP levels were found in hypoxemic COVID patients,
and a further correlation was observed between CRP and

mortality risk [2,5,34-36]. Troponin appears to be a strong
prognostic marker of mortality. Additionally, D-dimer
and ferritin levels were notably higher in hospitalized
patients in general. If necessary, patients with increased
CRP, lymphopenia and increased LDH should be followed
closely and transferred to ICUs. Various laboratory
features, including high D-dimer levels and more severe
lymphopenia, were associated with critical disease and
mortality [2,5,14,34-3].
In conclusion, COVID-19 is a novel viral disease with
the potential to affect almost every system and a rich
clinical spectrum, which results in varied complications
and is particularly severe and fatal in the elderly or those
with comorbidities, leading to pathological changes in
various laboratory tests.
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